Decreasing Hospital Admissions From the ED for AAFF
RAFF-3
1 other identifier
interventional
846
1 country
12
Brief Summary
Acute atrial fibrillation and flutter (AAFF) is characterized by rapid heart rates with onset less than seven days. It's the most common type of palpitation treated in the Emergency Department (ED). Some Canadian ED's will discharge 95% of AAFF patients whereas others admit up to 40%. With hospital and ED crowding, discharge is the most optimal, effective and safe strategy. Our aim is to improve the care and reduce the length of stay (LOS) of ED AAFF patients, while decreasing unnecessary hospitalizations. First, the investigators must understand the local barriers. In the previous study, the investigators conducted interviews of emergency physicians, cardiologists and AAFF patients. In Project 1b, the investigators created the CAEP ED AAFF Guidelines Checklist to assist physicians to manage AAFF more efficiently and safely. The Guidelines are comprised of two algorithms and four sets of checklists for ED assessment and management. They have been endorsed by CAEP and are published in CJEM. The investigators are now planning Project 2 in which the investigators will conduct a cluster \[group\] randomized trial at 11 Canadian EDs and enroll 1,300 patients over thirteen months. The investigators are not randomizing individual patients or doctors; instead the investigators are randomizing the start date of individual hospitals. Our goal is to introduce the new Guidelines into these hospitals to improve the care of AAFF patients. The investigators hope to improve AAFF management, leading to a significant decrease in hospital admissions and ED LOS. Central to our plans will be engagement of our two patient partners. Our behaviorally optimized intervention will be developed using state-of-the-art implementation science approaches informed by the results of Project 1a. The investigators will also undertake within-project and end-of-project knowledge translation and implementation (KTI) strategies to facilitate scale up and roll out of our program to ED departments in small, medium, and large hospitals across Canada (future Project 3). Ultimately the investigators expect to improve ED practices and decrease AAFF admissions and LOS, without increasing visits.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable atrial-fibrillation
Started Sep 2018
Shorter than P25 for not_applicable atrial-fibrillation
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2018
CompletedFirst Posted
Study publicly available on registry
August 13, 2018
CompletedStudy Start
First participant enrolled
September 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2019
CompletedJune 21, 2021
June 1, 2021
1.1 years
July 19, 2018
June 18, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
length of stay in ED in minutes
Length of stay in ED in min. from time of arrival to time of discharge or admission.
a 100 minute reduction in ED length of stay (or a relative reduction of approximately 25%)
Secondary Outcomes (5)
Use of rhythm control in the ED
13 months
Use of rate control and the final heart rate at disposition
13 months
Appropriate prescription of anticoagulants on discharge
1 day
Adverse events
30 days from discharge from the ED
Return ED visits and admission
30 days
Study Arms (1)
Local implementation of AAFF guidelines
OTHERThe study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
Interventions
The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients. 1. Selection of one or more local physician champions from both the ED as well as the cardiology group; 2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups; 3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources; 4. Development of local action plan addressing local barriers to implementation; 5. Provision of the free Smartphone App to be developed for the guidelines; 6. Regular reminders provided by the local research staff; 7. Audit and feedback charts of site compliance
Eligibility Criteria
You may qualify if:
- stable patients presenting with an episode of acute atrial fibrillation or flutter (AAFF) of at least 3 hours duration, where symptoms require ED management by rhythm or rate control.
- patients with a history of prior episodes of AAFF, or those with previous presentations during the study periods.
You may not qualify if:
- have permanent (chronic) AF
- are deemed unstable and require immediate cardioversion: i) systolic blood pressure \<90 mmHg; ii) rapid ventricular pre-excitation (Wolff-Parkinson-White syndrome); iii) acute coronary syndrome - ongoing severe chest pain and marked ST depression (\>2mm) on ECG despite therapy; or iv) pulmonary edema - severe dyspnea requiring immediate IV diuretic, nitrates, or BIPAP;
- the primary presentation was for another condition rather than arrhythmia
- convert spontaneously to sinus rhythm prior to receiving physician-initiated therapy; or
- die while in the ED from non-AAFF related causes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (12)
Dr. Georges-L. - Dumont University Hospital
Moncton, New Brunswick, Canada
Dartmouth General Hospital
Dartmouth, Nova Scotia, Canada
Ottawa Hospital
Ottawa, Ontario, K1Y 4E9, Canada
St. Joseph's Health Center
Toronto, Ontario, Canada
Hopital Du Sacre-Coeur
Montreal, Quebec, Canada
Hôpital Charles-Lemoyne
Montreal, Quebec, Canada
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Hôtel-Dieu de Lévis
Québec, Quebec, Canada
Regina General Hospital
Regina, Saskatchewan, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ian Stiell, MD
Ottawa Hospital Research Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 19, 2018
First Posted
August 13, 2018
Study Start
September 1, 2018
Primary Completion
September 30, 2019
Study Completion
October 30, 2019
Last Updated
June 21, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share